Desmopressin and indomethacin therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate

South Med J. 1990 Dec;83(12):1475-7. doi: 10.1097/00007611-199012000-00026.


Individuals receiving lithium carbonate commonly have nephrogenic diabetes insipidus. There is no effective and practical treatment for this condition. We have found that large doses of desmopressin (DDAVP) may provide effective therapy without adverse effects. A recent report showed that indomethacin improved nephrogenic diabetes insipidus that had persisted after the lithium therapy was discontinued. We have provided additional evidence that indomethacin may be effective, even when treatment with lithium is continued. We also have shown that indomethacin together with desmopressin can markedly decrease polyuria, though indomethacin must be used with care because it may impair renal function.

Publication types

  • Case Reports
  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects*
  • Deamino Arginine Vasopressin / administration & dosage
  • Deamino Arginine Vasopressin / therapeutic use*
  • Diabetes Insipidus / blood
  • Diabetes Insipidus / chemically induced*
  • Diabetes Insipidus / urine
  • Drug Evaluation
  • Drug Synergism
  • Drug Therapy, Combination
  • Female
  • Humans
  • Indomethacin / administration & dosage
  • Indomethacin / therapeutic use*
  • Injections, Subcutaneous
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / urine
  • Lithium / adverse effects*
  • Lithium Carbonate
  • Osmolar Concentration


  • Antiviral Agents
  • Lithium Carbonate
  • Lithium
  • Deamino Arginine Vasopressin
  • Indomethacin